Infinity Pharmaceuticals Inc. (INFI) Plunges 5.36% on October 28

Equities Staff  |

Infinity Pharmaceuticals Inc. (INFI) had a rough trading day for Wednesday October 28 as shares tumbled 5.36%, or a loss of $-0.06 per share, to close at $1.06. After opening the day at $1.10, shares of Infinity Pharmaceuticals Inc. traded as high as $1.11 and as low as $1.05. Volume was 286,169 shares over 787 trades, against an average daily volume of n/a shares and a total float of 58.87 million.

As a result of the decline, Infinity Pharmaceuticals Inc. now has a market cap of $62.4 million. In the last year, shares of Infinity Pharmaceuticals Inc. have traded between a range of $1.68 and $0.61, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

For a complete fundamental analysis of Infinity Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for INFI.

Still paying commissions on stock trades? Equities.com now offers $7.99/month unlimited trading and flat-fee options trading for $89.99/month! Get started today by https://www.equities.com/trading-start

Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment which is drug development.

Infinity Pharmaceuticals Inc. is based out of Cambridge, MA and has some 25 employees. Its CEO is Adelene Q. Perkins.

Infinity Pharmaceuticals Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Infinity Pharmaceuticals Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: INFI’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
GOOG

     
XOM

     
BRK.A

     
FB

     
JNJ

     
WFC

     
T

     
NFLX

     
TSLA

     
V

     
UNH

     
PG

     

Markets